BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 17693255)

  • 1. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.
    Lee DF; Kuo HP; Chen CT; Hsu JM; Chou CK; Wei Y; Sun HL; Li LY; Ping B; Huang WC; He X; Hung JY; Lai CC; Ding Q; Su JL; Yang JY; Sahin AA; Hortobagyi GN; Tsai FJ; Tsai CH; Hung MC
    Cell; 2007 Aug; 130(3):440-55. PubMed ID: 17693255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
    Nobukini T; Thomas G
    Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.
    El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ
    Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
    Kwiatkowski DJ; Manning BD
    Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
    Ma L; Teruya-Feldstein J; Bonner P; Bernardi R; Franz DN; Witte D; Cordon-Cardo C; Pandolfi PP
    Cancer Res; 2007 Aug; 67(15):7106-12. PubMed ID: 17671177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinases meet at TSC.
    Wu Y; Zhou BP
    Cell Res; 2007 Dec; 17(12):971-3. PubMed ID: 18075516
    [No Abstract]   [Full Text] [Related]  

  • 7. TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation?
    Findlay GM; Harrington LS; Lamb RF
    Curr Opin Genet Dev; 2005 Feb; 15(1):69-76. PubMed ID: 15661536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation and binding partner analysis of the TSC1-TSC2 complex.
    Nellist M; Burgers PC; van den Ouweland AM; Halley DJ; Luider TM
    Biochem Biophys Res Commun; 2005 Aug; 333(3):818-26. PubMed ID: 15963462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway.
    Jiang X; Yeung RS
    Cancer Res; 2006 May; 66(10):5258-69. PubMed ID: 16707451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All roads lead to mTOR: integrating inflammation and tumor angiogenesis.
    Lee DF; Hung MC
    Cell Cycle; 2007 Dec; 6(24):3011-4. PubMed ID: 18073529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TSC-mTOR signaling pathway regulates the innate inflammatory response.
    Weichhart T; Costantino G; Poglitsch M; Rosner M; Zeyda M; Stuhlmeier KM; Kolbe T; Stulnig TM; Hörl WH; Hengstschläger M; Müller M; Säemann MD
    Immunity; 2008 Oct; 29(4):565-77. PubMed ID: 18848473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes.
    Brugarolas J; Kaelin WG
    Cancer Cell; 2004 Jul; 6(1):7-10. PubMed ID: 15261137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IKKbeta suppression of TSC1 function links the mTOR pathway with insulin resistance.
    Lee DF; Kuo HP; Chen CT; Wei Y; Chou CK; Hung JY; Yen CJ; Hung MC
    Int J Mol Med; 2008 Nov; 22(5):633-8. PubMed ID: 18949383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
    Goncharova EA; Krymskaya VP
    J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway.
    Chen W; Ma T; Shen XN; Xia XF; Xu GD; Bai XL; Liang TB
    Cancer Res; 2012 Mar; 72(6):1363-72. PubMed ID: 22287548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle atrophy in transgenic mice expressing a human TSC1 transgene.
    Wan M; Wu X; Guan KL; Han M; Zhuang Y; Xu T
    FEBS Lett; 2006 Oct; 580(24):5621-7. PubMed ID: 16996505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin.
    Jin T; George Fantus I; Sun J
    Cell Signal; 2008 Oct; 20(10):1697-704. PubMed ID: 18555664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IKK/NF-kappaB signaling pathway inhibits cell-cycle progression by a novel Rb-independent suppression system for E2F transcription factors.
    Araki K; Kawauchi K; Tanaka N
    Oncogene; 2008 Sep; 27(43):5696-705. PubMed ID: 18542057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.
    El-Hashemite N; Walker V; Kwiatkowski DJ
    Cancer Res; 2005 Mar; 65(6):2474-81. PubMed ID: 15781664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tsc1 deficiency-mediated mTOR hyperactivation in vascular endothelial cells causes angiogenesis defects and embryonic lethality.
    Ma A; Wang L; Gao Y; Chang Z; Peng H; Zeng N; Gui YS; Tian X; Li X; Cai B; Zhang H; Xu KF
    Hum Mol Genet; 2014 Feb; 23(3):693-705. PubMed ID: 24129405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.